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Abstract
Background: There is no known biochemical basis for the adverse neurological events attributed
to mefloquine. Identification of genes modulated by toxic agents using microarrays may provide
sufficient information to generate hypotheses regarding their mode of action. However, this utility
may be compromised if sample sizes are too low or the filtering methods used to identify
differentially expressed genes are inappropriate.
Methods: The transcriptional changes induced in rat neuroblastoma cells by a physiological dose
of mefloquine (10 micro-molar) were investigated using Affymetrix arrays. A large sample size was
used (total of 16 arrays). Genes were ranked by P-value (t-test). RT-PCR was used to confirm (or
reject) the expression changes of several of the genes with the lowest P-values. Different P-value
filtering methods were compared in terms of their ability to detect these differentially expressed
genes. A retrospective power analysis was then performed to determine whether the use of lower
sample sizes might also have detected those genes with altered transcription.
Results: Based on RT-PCR, mefloquine upregulated cJun, IkappaB and GADD153. Reverse Holm-
Bonferroni P-value filtering was superior to other methods in terms of maximizing detection of
differentially expressed genes but not those with unaltered expression. Reduction of total
microarray sample size (< 10) impaired the capacity to detect differentially expressed genes.
Conclusions: Adequate sample sizes and appropriate selection of P-value filtering methods are
essential for the reliable detection of differentially expressed genes. The changes in gene expression
induced by mefloquine suggest that the ER might be a neuronal target of the drug.
Background
Mefloquine (Lariam) is a prophylactic antimalarial that is
also used for malaria chemotherapy. Adverse central nerv-
ous system (CNS) events have been associated with its
use. Severe CNS events requiring hospitalization occur in
1:10,000 and 1:200–1200 patients taking mefloquine for
chemoprophylaxis and treatment, respectively [1]. Milder
CNS events (e.g. dizziness, headache and insomnia) are a
more frequent occurrence, occurring in up to 25% of
those receiving chemoprophylactic doses and 90% of pa-
tients receiving therapeutic doses [1]. Higher blood levels
of mefloquine are reached under prophylactic as com-
pared to therapeutic regimens [1,2]. The relative incidence
of adverse effects is, therefore, probably dose-related,
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although the concomitant effect of malaria during treat-
ment cannot be dismissed. It is likely, then, that the
neurological events associated with mefloquine have a bi-
ochemical basis. In this study, an attempt was made to de-
duce a possible mechanism of action for mefloquine in rat
neuronal cells using Affymetrix rat toxicology arrays.
Microarray analysis offers the unique potential to identify
unknown targets of toxic agents, as transcriptional re-
sponses of the entire genome can be measured in parallel
[3]. Ideally, one should be able to identify new targets
quickly, confidently, and without recourse to alternative
methods. Appropriate selection of a method for filtering
gene expression data is therefore critical to this process.
One of the first definitions to emerge was the arbitrary
designation of a particular level of – usually two-fold up
or down regulation – gene expression as representing 'sig-
nificance' [4,5]. Such arbitrary definitions emerged from
the observation that fold-regulation of genes between
control cultures with identical cell populations seldom
varies by more than this level (discussed by Ideker et al.
[6]).
However, arbitrary designations cannot be considered
'significant' in the traditional, statistical sense unless ex-
perimental variance is taken into consideration. An evolv-
ing method of analysis is to define significant changes in
gene expression in terms of a particular P-value after per-
forming appropriate statistical tests that take into account
the variability of gene expression data and sample size [6–
10]. However, care must be taken to use appropriate sta-
tistical tests, P-value thresholds for significance, and suffi-
cient n, otherwise, variance-based methods, as with less
rigorous fold-change approaches, will generate high error
rates. Recent studies have discussed the utility of the 'Z
score', the parametric t-test, and the nonparametric Wil-
coxon rank sum test for expression profiling [9,10]. How-
ever, the effects of inadequate sample size and P-value
correction methods are only beginning to be addressed
[11].
Due to restrictions on the type and availability of biologi-
cal samples and the prohibitive cost of arrays, many array
studies have resorted to the use of extremely low sample
sizes (for a recent example see Lang et al. [12]). This is po-
tentially problematic because the power of statistical tests
decreases with sample size. There is also the multiplicity
problem [13]. As the number of hypotheses being tested
increases so does the number of type I errors (false conclu-
sions of significance). This is of great concern in microar-
ray studies given the number of statistical comparisons
being made (i.e. one test per gene on an array). Therefore,
P-value correction is essential in expression profiling to
control an appropriate type 1 error rate, although undue
conservatism may result in the failure to detect transcrip-
tional changes for some genes that might indeed be verifi-
able by other means. As shown in this study, adoption of
an experimental design that incorporates an adequate
sample size and appropriate selection of a P-value filtering
method is critical if genes with altered transcription are to
be efficiently and effectively identified.
Materials and Methods
Reagents and media
Mefloquine was obtained from Walter Reed Army Insti-
tute of Research chemical repository. Dulbecco's Modified
Eagle Medium (DMEM), hypoxanthine-aminopterin-thy-
midine (HAT) medium supplement, foetal calf serum
(FCS) and gentamycin were purchased from Gibco BRL
(Rockville, Maryland). RNA-STAT was obtained from Tel-
Test (Friendswood, Texas).
Cell maintenance
NG108-15 (mouse neuroblastoma-rat glioma hybrid)
cells were maintained in 75-cm2 tissue culture flasks in
DMEM supplemented with HAT, 10% FCS and gentamy-
cin (50 µg/ml), in a humidified 6.0% CO2 incubator at
37°C. For the microarray studies, 175 cm2 tissue culture
flasks were seeded with 4.6 million NG108 cells in 49.6
ml culture medium 24 h prior to the experiments. For cy-
totoxicity studies, 25 cm2 tissue culture flasks were seeded
with 0.66 million NG108 cells in 10 ml culture medium
24 h prior to the experiment.
Cytotoxicity of mefloquine in NG108 and primary rat neu-
ronal cell cultures
The cytotoxicity of mefloquine was assessed using 25 cm2
tissue culture flasks. After overnight incubation of NG108
cells, culture media were replaced with fresh DMEM con-
taining mefloquine (2.5–40 µM) or 1% DMSO (control).
After incubation of the flasks for 2 h, the cells were washed
twice, and then resuspended, in 5 ml phosphate buffered
saline. Total numbers of viable cells at each mefloquine
concentration were determined using trypan blue exclu-
sion as previously described [14]. Viability (%) was calcu-
lated using the following formula: Viability (%) = # viable
cells in treated culture/# viable cells in control culture *
100. Data shown represent the mean (%) viability (±
SEM) for three experiments. The cytotoxicity of meflo-
quine to primary embryonic rat neurons was assessed in
24 well tissue culture plates using the MTT assay as previ-
ously described [15]. Data represent mean (%) viability (±
SEM) for eight replicate experiments. Fifty percent inhibi-
tory concentrations (IC50s) were calculated using Prism
software.
Design of microarray experiments, cell harvesting and to-
tal RNA extraction
On the day of the experiment, the media was removed
from the seeded flasks and replaced with 70 ml DMEMMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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supplemented with either 0.25% DMSO (controls) or 10
µM mefloquine in 0.25% DMSO (treated). The cells were
treated with mefloquine or DMSO for 2 h. This treatment
regime reduces the viability of NG108 cells by approxi-
mately 35% (Figure 1). After incubation, media was re-
moved and replaced with 15.0 ml RNA STAT (Tel-Test,
Friendswood Texas). Total RNA was then extracted ac-
cording to the manufacturer's instructions. Eight pairs of
RNA samples (eight control and eight treated samples)
were collected on different occasions.
CDNA synthesis, in vitro transcription and fluorescent la-
beling, hybridization, staining and scanning of gene chips, 
and assay monitoring
Detailed procedures for preparation of cDNA and fluores-
cently labeled cRNA, hybridization, staining, and scan-
ning of gene chips and assay monitoring are outlined by
Vahey et al. [16]. The platform chosen for global expres-
sion profile was the Rat Tox U34 Array (Affymetrix, Santa
Clara, California), which contains probes for EST clusters
and genes linked to a variety of toxic endpoints (total of
1031 probe sets including controls). RNA (10 µg) extract-
ed from each individual flask was hybridized to a single
gene chip (i.e. a total of 16 chips were used).
Gene expression data analysis
Affymetrix analysis software (version 4) was used to gen-
erate average difference (AD) values for each gene for each
treatment (Affymetrix, Santa Clara, California). AD values
represent the difference in mean fluorescence between
positive and mismatch probe cells for each gene. All genes
with mean AD levels < 100 in either mefloquine or
DMSO-treated cultures were excluded. This procedure
eliminated most of the genes called absent by the Affyme-
trix software. For simplicity, an AD value is hereafter re-
ferred to as the expression value of a gene. The expression
values for each gene chip were imported directly into
Parteck Pro 2000. No additional data normalization or
scaling methods were employed (as these procedures were
performed previously by the Affymetrix software). No ad-
ditional filtering of data was conducted on the basis of ei-
ther number of reporting probe cells or the present/absent
calls generated by the Affymetrix analysis software. Paired
t-tests (two-sided, df = 7) were performed to compare the
expression levels of each of the remaining genes (695 of
1031) in DMSO and mefloquine-treated cultures. The
genes were then rank ordered in terms of their unadjusted
P-values. This general approach to the analysis of Affyme-
trix expression data is outlined in Partek technical litera-
ture. Fold-changes (FC) in expression were = mean
mefloquine expression level/mean DMSO expression
level.
Figure 1
Dose response curves for mefloquine against rat neuroblastoma (NG108) and primary embryonic rat neuronal cells.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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Expression data generated for this study is available from 
GEO (Accession #GSE39 for a summary of the experiment 
and GSM1654-1669 for individual treatments)
RT-PCR validation
PCR following reverse transcription was performed for
semi-quantitative determination of steady-state expres-
sion of RNA for tubulin (negative control) and six of the
eleven lowest P-value ranked transcripts (see RT-PCR con-
ditions in Table 1). For each sample, 2 µg RNA was tran-
scribed in a 20 µl reaction using the Invitrogen
SuperScript First-Strand Synthesis System oligo-(dT)
primer method according to the manufacturer's instruc-
tions. cDNA was RNase-treated (E. coli RNAse H at 37°C
for 20 min) and diluted to 400 µl in molecular biology
grade water prior to PCR. For each gene, 5 µl of cDNA was
incorporated into a 25 µl PCR mixture containing 8.8 mM
TrisHCL, 44 mM KCl, 1.3 mM MgCl2, 0.00088 % gelatin,
0.284 mM each deoxynucleoside triphosphate, 1 U of Taq
DNA polymerase (Applied Biosystems, Foster City, CA)
and 1.78 µM of each primer. After an initial denaturation
of 94°C for 5 min, cycles consisted of 30 sec denaturation
at 94°C, 30 sec of primer annealing at a gene specific an-
nealing temperature and 60 sec of primer extension at
72°C, followed by a final elongation step of 72°C for 5
min. Cycle numbers were chosen such that amplification
was in the linear range of detection. PCR products (20 µl)
were electrophoresed on ethidium bromide-stained 1.2%
agarose gels, revealed by UV illumination and analyzed
densitometrically. Gene specific primer sequences, cycle
times and annealing temperatures are outlined in Table 1.
For each transcript, raw densitometry data was subjected
to paired t-testing (two-sided, df = 7) to determine wheth-
er differences in expression existed in mefloquine and
DMSO-treated cultures (P < 0.05).
Designation of a list of genes with altered expression
The mefloquine data set was used to compare several P-
value correction and gene expression filtering methods.
The methods were compared in terms of their ability (or
failure) to detect genes defined as having (truly) altered
expression. Genes with altered changes in expression were
those with an array P < 0.003. This threshold was selected
because of the good correlation of microarray and RT-PCR
P-values and because it represents the highest unadjusted
P-Value for which an associated mefloquine-induced ex-
pression change was confirmed by RT-PCR.
Descriptions of different gene expression filtering methods
Genes were filtered on the basis of their unadjusted P-val-
ues according to several different methods: (i) The normal
P < 0.05 threshold (i.e. P < 0.05 for significance), (ii) the
modified Bonferroni's step-down procedure of Holm or
(iii) the Holm-Bonferroni procedure applied in reverse
with initial P-values of 0.05 or 0.01. Applying the Holm
step-down procedure [13], the P-value threshold for sig-
nificance for each genes is determined on the basis of its
rank according to the following formula: P = 0.05/(total
number of t-tests or genes in array + 1 – gene rank). There-
fore, the gene ranked 1 (i.e. having the lowest P-value) in
an expression set for which 695 statistical tests are to be
conducted, the threshold P-value is 0.05/695. For the low-
est ranked gene (i.e. with the highest P-value) the thresh-
old is 0.05/1. This method was also applied in reverse,
utilizing starting P-values of 0.05 and 0.01, according to
the following formula: P = (0.05 or 0.01)/gene rank. This
approach is hereafter referred to as the reverse Holm
procedure. For comparison, the expression data were also
filtered using an ad hoc fold-change method. For the fold-
change method, the expression ratios were calculated for
each gene and a two-fold change was used as the criterion
for significance.
Power analysis using mefloquine data set
In general, when using statistical tests (in this case a paired
t-test), the required sample size to detect a particular
change (e.g. treatment versus control) depends on the
magnitude of the difference, variability of the data, the re-
quired statistical power and the acceptable type 1 error.
The mefloquine data set was used to assess the power and
implications of sample size in terms of the minimum de-
tectable average fold-change in expression of the six genes
defined as being truly upregulated by the drug. First, a
publicly available power/sample size calculator ([17],
available at http://www.mc.vanderbilt.edu/prevmed/ps)
was used to determine the power of the paired test (two-
sided, df = 7). Then, based on this level of power and the
Table 1: Gene specific primers, cycles, product sizes and annealing temperatures.
Accession # Cycles Product Size (bp) Annealing Temperature °C Forward Primer (5'– 3') Reverse Primer (5'-3')
X63594 30 485 56 CTGAAAGCTGGCTGTGATCC TCCGTGTCATAGCTCTCCTCA
U30186 25 416 56 CTGGAAGCCTGGTATGAGGA CGCCGTGTGGTCTCTACCT
AI75959 35 421 56 CACTGGGTAGGACACCCAAA CCAGAACGATGGACTTTTCG
AI237378 30 414 54 GGAGCAGCAGGCTCTAGGTT CTCGAGGAGCTAAAAGCCAAG
M15114 25 501 56 AGTGCCGTAGCTGATGGATG CCTACCCGTGGAGGTAGGTC
X54686 35 498 54 ATCAGACACAGGCGCATCTC TCCTCTTTAAAGGCGGAAGC
Tubulin 25 589 62 CACTTCCCTCTGGCCACTTA GTGAAAGCAGCACCTTGTGAMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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same critical values, absolute change in expression was
calculated at different sample sizes. The critical values for
the calculations were as follows. The detectable difference
(δ) was the absolute, average changes in the expression
values of the control group. The standard deviation (σ)
was the square root of the average variance of differences
in expression of the six genes in individual pairs of DMSO
and mefloquine-treated cultures. The type 1 error (two-
sided) was set at α = 0.003, which corresponded to the
maximum  P-value for which expression changes were
confirmed by RT-PCR. Absolute changes in expression at
different sample sizes are presented as minimum detecta-
ble fold-changes in expression using the following formu-
la: Minimum detectable fold-change = (average
expression value of the six upregulated genes in control
cultures + size of the detectable difference)/average ex-
pression value of the six upregulated genes in control
cultures.
Results
NG108 and primary embryonic rat neuronal cells were
similarly susceptible to mefloquine. The IC50s of the drug
against NG108 cells and primary neurons were 12 and 6.6
µM respectively and the overall shapes of the dose re-
sponse curves were similar (Figure 1).
The eleven genes with the lowest (array) P-values are pre-
sented in Table 2. The upregulation by mefloquine of
transcripts encoding the transcription factors cJun and
IkappaB (IkB) and the ER stress protein GADD153 were
confirmed by RT-PCR (Table 2, Figure 2). All the genes
listed in Table 2 had P-values for the microarray expres-
sion data substantially less than 0.05. However, expres-
sion changes were only confirmed for those genes with
array P-values < 0.003. Also, there was a good correlation
between P-values for the microarray and RT-PCR expres-
sion data (r = 0.97. P < 0.002, Figure 3). Therefore, the sev-
en genes with array P-values < 0.003 were considered to
have expression truly altered by mefloquine (Table 2).
The fold-change and P-value filtering methods were com-
pared in terms of their ability to detect (not detect) genes
differentially modulated by mefloquine (Table 3). The
fold-change and P < 0.05 filtering methods detected all
seven differentially expressed genes, but also identified
many other genes which, given their relatively high unad-
justed P-values, are unlikely to be differentially expressed
Figure 2
Semi-quantitative RT-PCR of tubulin, pJunB, EST cJun (AI175959), IkappaB and GADD153 mRNA from DMSO or mefloquine-
treated NG108 rat neuronal cell cultures. cDNA was synthesized using oligo-(dT) primers and amplified using gene specific 
primers. Results are expressed relative to mean optical density for DMSO samples for each gene. (* P value < 0.05, two-sided 
paired t-test, df = 7).Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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(i.e. are probably false positives). The Holm-Bonferroni
procedure failed to detect any differentially expressed
genes. Other conservative filtering methods described in
the literature [13] performed similarly poorly (e.g. the
Sidak and Hochberg procedures). The reverse Holm pro-
cedures detected more significant genes than the Holm-
Bonferroni method and generated fewer false positive re-
sults than the P < 0.05 method. However, the more con-
servative reverse Holm method (initial P < 0.01) failed to
identify two significant genes.
The effect of sample size on the ease of detection of meflo-
quine-induced transcriptional changes was then exam-
ined. The power of a paired t-test capable of detecting the
average change in expression of the six genes upregulated
by mefloquine was found to be 50%. The effect of sample
size on the minimum fold-change detectable using a test
of such power is illustrated in Figure 4. The minimum de-
tectable fold-change increased with decreasing sample
size. Reduction of total sample size from 16 to 12 modest-
ly increased the minimum detectable fold-change from
3.0 to 3.8. At a total sample size lower than 10, the mini-
mum detectable fold-change exceeded the maximum
change in expression induced by mefloquine.
Discussion
The detection of differentially expressed genes depends
critically on having adequate replication (sample size)
and on the selection of appropriate filtering methods (in
the case of this study a P-value filtering method). In terms
Figure 3
P-Values (paired, two sided t-test, df = 7) for RT-PCR and microarray expression data (DMSO v mefloquine-treated NG108 
cells) are highly correlated (r = 0.97, P < 0.002).Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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of their ability to detect genes differentially modulated by
mefloquine, the different P-value filtering methods can be
ranked in terms of their conservativeness as follows:
Holm-Bonferroni > reverse Holm (initial P < 0.01) > re-
verse Holm (initial P < 0.05) > no correction (i.e. P <
0.05). These results are not surprising if one considers the
distribution of observed (unadjusted) microarray P values
and that expected (uniform if independent tests) under
the complete null hypothesis that all genes are unaltered
(Figure 5). Application of the reverse Holm procedures
generates relatively few false positive results compared to
no P-value correction, but detects genes more efficiently
than if the Holm-Bonferroni procedure is applied.
This, of course, begs the question as to whether it is appro-
priate to now conclude that the reverse Holm procedure is
the most appropriate P-value filtering method. The an-
swer, of course, depends on the goal of the proposed
study. If, for example, one wished to be certain that a gene
is differentially expressed, or does not wish to resort to la-
borious conventional techniques to confirm expression
changes, the only appropriate filtering method is the Bon-
ferroni (or other related) procedure, as the chance of gen-
erating false positive results using such methods is
negligible. However, if one wishes to identify all differen-
tially expressed genes, and possesses the resources
necessary to confirm all expression changes using tradi-
tional approaches, the P  < 0.05 threshold (or a fold-
change method) might be the most appropriate. However
for many studies that do not fall at either of these ex-
tremes, application of a reverse Holm procedure might be
the most appropriate choice.
The choice of an appropriate sample size is also critical if
(true) differentially expressed genes are to have a high
probability of being detected. A power analysis was con-
ducted to determine whether the transcriptional changes
induced by mefloquine might have been detectable using
lower sample sizes. There was a modest increase in the
minimum detectable fold-change of an average gene
when the sample size was reduced to twelve from sixteen.
In theory, then, a modest reduction in sample size may
Table 2: Transcriptional changes induced in rat neuroblastoma (NG108) cells by a two-hour treatment with 10 µM mefloquine.
Gene Accession Fold-change P-value1 Result of RT-PCR
(Expression Designation)2
GADD153 U30186 4.6 0.00013 Confirmed (altered)
IkappaB X63594 2.2 0.00059 Confirmed (altered)
IkappaB X63594 2.8 0.0014 Not tested (altered)
CJun X17163 5.9 0.00165 Not tested (altered)
Dual specificity 
phosphatase
X94185 0.58 0.00184 Not tested (altered)
EST-cJun AA945867 2.2 0.00186 Not tested (altered)
EST-cJun AI175959 3.6 0.00282 Confirmed (altered)
DNA Polymerase α M15114 1.3 0.00339 Not confirmed (unaltered)
PjunB X54686 2.0 0.00383 Not confirmed (unaltered)
Acyl CoA hydrolase AB010428 1.7 0.00391 Not tested (unaltered)
Unknown EST AI237378 0.72 0.00663 Not confirmed (unaltered)
Notes 1. Paired t (df = 7) comparing mefloquine and DMSO (array data). 2. Expression was either confirmed (paired t-test, df = 7, P < 0.05) not con-
firmed (paired t-test, df = 7, P > 0.05) by RT-PCR or RT-PCR was not conducted (not tested). For the purposes of comparing the utility of different 
expression data filtering methods, genes were defined as having altered (array P < 0.003) or unaltered (array P > 0.003) expression. This threshold 
represents the highest array P-Value for which expression changes could be (were) confirmed by RT-PCR.
Table 3: Detection (or rejection) of differentially expressed genes using various P-value correction methods.
Fold-change > 2 P < 0.05 Reverse Holm Procedure Holm-Bonferroni
No of ... P < 0.05 P < 0.01
Significant genes 27 33 10 5 0
Differentially expressed genes detected1 77 7 50
Differentially expressed genes rejected1 00 0 27
Notes 1. Altered expression of a gene was established using RT-PCR.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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still have allowed many significant genes to be detected.
However at sample sizes below ten, the minimum
detectable fold-change exceeded the maximum transcrip-
tional modulation of any gene by mefloquine, implying
that such changes would be extremely difficult if not im-
possible to detect. These observations may be directly rel-
evant for planning future studies in which transcriptional
changes of similar magnitude, and data-sets with similar
variance characteristics, are expected. However, such a
power analysis might be considered conservative for stud-
ies in which larger magnitude fold-changes are expected.
Appropriate experimental design is also necessary to en-
sure that any changes in gene expression observed are rel-
evant to the problem being investigated. The choice of cell
system, toxicant concentration and exposure time must all
be carefully considered. In the present study, an immortal
(NG108) cell line was selected as these cells are easier to
maintain in vitro and large amounts of RNA can be rou-
tinely isolated. Cell lines do not always respond in the
same manner that untransformed cells would in an in vivo
context; therefore their use in experimental model sys-
tems may not always be appropriate. However, this does
not appear to be the case for mefloquine, since NG108
cells and primary embryonic rat neurons appear similarly
susceptible to the drug (Figure 1). The mefloquine con-
centration (10 µM) was selected on the basis of its physi-
ological relevance [18–20] and ability to elicit a
Figure 4
Power analysis of sample size versus minimum detectable fold-change for mefloquine-modulated genes. Calculations were per-
formed with PS software (Dupont and Plummer, 1990), using the following critical values: Power = 0.5, α = 0.003, σ = 1686 
(based on an average control expression value of 1315), with total sample size ranging from 4–16. Reduction of sample size 
from 16 to 12 resulted in a modest increase in the minimum detectable fold-change. Reduction of total sample size to less than 
10 results in elevation of the minimum detectable fold-change above the maximum transcriptional modulation induced by 
mefloquine.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
Page 9 of 11
(page number not for citation purposes)
measurable physiological response without inducing
maximum cell death (Figure 1). A short exposure time (2
h) was selected for two reasons. Firstly, shorter toxicant ex-
posure time ensured that any changes observed in specific
mRNA transcript levels were due to the direct cellular ef-
fects of mefloquine, rather than secondary effects caused
by changing culture conditions (since drug-treated
NG108 cells divide less rapidly than DMSO-treated cells).
Secondly, a short in vitro exposure time is appropriate
since the adverse neurological effects of mefloquine in vivo
occur within 24–48 hours of the first 1–2 doses adminis-
tered [21,22].
Mefloquine induced changes in the expression of three
genes, GADD153, IkB and cJun. CJun is a transcription
factor upregulated in response to many forms of neuro-
logical injury [23], thus its modulation by mefloquine un-
der conditions of cellular stress is unsurprising and does
not imply a specific mechanism of action. However, this
is not the case for GADD153 and IkB. Two highly con-
served responses are observed under conditions of endo-
plasmic reticulum (ER) stress; the ER overload and
unfolded protein responses [24,25]. The unfolded protein
response is characterized by generalized suppression of
protein synthesis and the specific induction of ER-resident
proteins and GADD153 [24]. The transcription factor nu-
clear factor kB is activated during the ER overload
response, leading to the downstream induction of pro-in-
flammatory proteins [25]. Therefore, the transcriptional
modulation of GADD153 and IkB by mefloquine suggests
that the ER might be a target of the drug.
In neurons, GADD153 is selectively upregulated under
conditions of endoplasmic reticulum (ER) stress arising
from depletion of calcium stores [26]. Here, the upregula-
tion of GADD153 was observed after mefloquine treat-
Figure 5
P-value distributions for mefloquine and theoretical null data sets and threshold trend-lines for the various P-value filtering 
methods. The section of the null P-value distribution below the intersections with the various P-value threshold lines repre-
sents the relative likelihood of generating false positive results. The section of the mefloquine P-value distribution below the 
intersections with the various P-value threshold lines represents the relative likelihood of detecting differentially expressed 
genes. The Holm-Bonferroni procedure fails to detect genes significantly altered by mefloquine, but has a low false positive 
rate. The use of the traditional P < 0.05 filter will detect all differentially expressed genes but will inevitably be associated with 
a high false positive rate. The two reverse Holm procedures detected most differentially expressed genes and are associated 
with much lower false positive error rates than the traditional P < 0.05 filter.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/4
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ment in NG108 cells (10 µM for 2 h). In preliminary
experiments utilizing primary rat neurons, we have also
observed an upregulation of GADD153 after mefloquine
treatment (unpublished data). Mefloquine has been
found to alter calcium flux, into and out of, isolated
skeletal muscle and brain microsomes, via an inhibitory
effect of the compound on the ER calcium pump and cal-
cium release channels (IC50  of 42–43 uM, [27,28]).
Plasma mefloquine concentrations (therapeutic dosing)
may reach 21 µM [18] and the drug crosses the blood-
brain barrier, accumulating to concentrations in excess of
50 and 90 µM in the brains of humans and rats respective-
ly [19,20]. Therefore, these biochemical effects occur at
concentrations within a relevant physiological range. Col-
lectively, these observations suggest that mefloquine dis-
rupts neuronal function through a combination of
disrupted calcium homeostasis and ER stress. This hy-
pothesis is currently under investigation in this
laboratory.
Conclusions
Adequate sample sizes and appropriate selection of P-val-
ue filtering methods are essential for the efficient and ef-
fective detection of differentially expressed genes.
Mefloquine induced changes in the expression of genes
encoding cJun, IkB and the ER stress response protein
GADD153. The upregulation of GADD153 by meflo-
quine suggests that the drug might affect the function of
the ER in neurons, perhaps by disruption of calcium
homeostasis.
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